

Index

INDEX

A

Access, 78
 Action research, 74
 Active case finding, 71
 Adherence, 74
 Africa, 38, 39
 Alderton, Heidi, 58
 Ambrose, Lyn, 62
 Antigen presentation, 51
 Antiretrovirals, 52
 Anti-TNF therapy, 55
 ART, 15, 17, 28
 Atopy, 43
 Ayles, Helen, 9, 10, 11, 23, 24, 25, 26, 69, 74

B

Babiker, Abdel, 32
 Bancroft, Greg, 55, 58, 65
 Banda, Joseph, 9, 10, 11
 BCG, 41, 42, 43, 44, 53, 59, 61, 63
 - efficacy of a second dose, 44
 Ben-Smith, Anne, 54, 59, 63
 Bickle, Quentin, 65
 Biomarkers, 60, 62, 63
 Biostatistics, 30
 Boccia, Delia, 24, 26
 Bond, Virginia, 26, 69, 73
 Branson, Keith, 33, 34, 35, 36, 54
 Brazil, 41

C

Case control, 34
 Cheung, Yin Bun, 39
 Cho Jang-Eun, 60
 Cliff, Jackie, 60
 Cohort, 28, 38, 39, 47, 56
 Coldham, Alexandra, 26, 69
 Communicable disease, 69
 Community-level, 30
 Corbett, Liz, 25, 29, 38, 39
 Cost-effectiveness, 15, 16, 17, 18, 19
 Costs, 15, 16, 17, 18
 Cotrimoxazole, 16, 18
 Crampin, Amelia, 33, 34, 35, 36, 54, 59
 CREATE, 25
 Cytokines, 43, 56, 57, 59, 63, 65

D

Day, John, 16, 27
 De Haas Petra, 69
 De Reynal, Melanie, 65
 Demand, 75
 Diagnosis, 6, 7, 8, 9, 10, 11, 62
 Diagnostic process, 74
 Diagnostic tests, 64
 Disease progression, 27
 Dissemination, 69
 Dockrell, Hazel, 33, 34, 52, 53, 54, 56, 57, 59, 60, 61, 62, 63, 64
 Drug development, 60
 Drug resistance, 3, 4, 5, 23, 25
 Duong, Trinh, 56

E

Economics (see also chapter heading), 15, 16, 17, 18
 Elliott, Alison, 3, 56
 Epidemiology (see also chapter headings), 52, 71
 Equity, 75
 Ethics, 76
 Evaluation, 70
 Exposure, 54

F

Fielding, Katherine, 15, 16, 25, 27, 28, 29, 30, 31, 32
 Fingerprinting, 44
 Fine, Paul, 33, 34, 35, 36, 37, 46, 54, 59, 63
 Floyd, Sian, 33, 34, 35, 36, 54, 57
 Food insecurity, 73
 French, Neil, 34, 62, 63

G

Gatifloxacin, 31
 Gender, 33, 70
 Gene expression profiling, 60
 Genetics, 35, 58, 60
 Geographical distribution, 44
 Glynn, Judith, 33, 34, 36, 37, 47
 Gorak-Stolinska, Patricia, 59
 Grant, Alison, 15, 16, 25, 27, 28, 29
 Godfrey-Faussett, Peter, 4, 6, 9, 10, 11, 23, 24, 25, 26, 29, 46, 69, 74

H

Hanson, Kara, 75
 Hayes, Richard, 16, 25, 26, 27, 29, 30, 56
 Health inequalities, 24, 75
 Health seeking behaviors, 24
 Health service use, 75
 Helmbj, Helena, 65
 Helminths, 43, 56, 65
 Hesseling, Anneke, 46
 HIV, 16, 18, 25, 26, 27, 28, 30, 33, 35, 36, 37, 39, 46, 47, 54, 62, 63, 75, 76, 77
 -testing, 76, 77, 81
 -counselling, 76, 77
 HIV/AIDS, 15, 17, 52, 70, 72, 73, 81
 Hospitals, 81
 Host-pathogen interactions, 58
 Houben, Rein, 37
 Hurst, Tamara, 56
 Hypervirulence, 58

I

Implementation, 81
 Immune reconstitution, 52
 India, 76, 77, 78, 81
 Infants, 46
 Informed consent, 76
 Innate immunity, 51
 Intracellular survival, 51

J

Jan, Stephen, 70

K

Kaye, Paul, 55
 Kielmann, Karina, 69, 76, 77, 78
 Kim, Julia, 70
 Korbelt, Daniel, 51
 Korea, 61
 Kumaranayake, Lilani, 15, 16, 17, 18, 19

L

Lalor, Maeve, 59, 63
 Lawn, Stephen D, 52
 Lee, Hyejon, 61
 Leprosy, 64
 Lewis, James, 29, 30

Lockwood, Diana

M

Macrophage, 51
 Malawi, 18, 33, 34, 35, 36, 59, 62, 63
 Malaysia, 45
 Mallard, Kim, 5, 6, 23, 69
 Management practices, 77
 Mathematical modelling, 37
 Mabey, David, 56
 McGrath, Nuala, 33, 59, 63
 McMinn, Liz, 55
 McNerney, Ruth, 3, 4, 5, 6, 7, 8, 9, 10, 11, 23, 69
 MDR, 44
 MDT-TB, 3, 4, 5
 Medical regulation, 81
 Merle, Corinne, 31
 Microfinance, 70
 Millennium development goals, 69
 Mills, Anne, 75
 Molecular epidemiology, 4, 23, 27, 36, 64
 Morison, Linda, 70
 Mortality, 25
 Mueller, Dirk, 9, 10, 26, 69
 Mulholland, Kim, 46
 Multicentre, 31

N

O

Olfactory sensing, 6

P

Palmer, Natasha, 39
 Paradigms, 25, 26
 Phagosome, 51
 Phillips, Patrick, 32
 Policy (see also chapter heading), 25, 26
 Policy analysis, 81
 Porter, John, 39, 69, 70, 76, 77, 78, 81
 Poverty, 24
 Poverty alleviation, 70
 Private medical sector, 77
 Program evaluation, 44
 Pronyk, Paul, 70, 71, 72
 Provider initiated testing, 81

Public-private partnerships, 19

Q

Quality of care, 78

R

Randomised controlled trial, 29

RCT, 30, 31

Resource requirements, 19

RFLP, 27

Rodrigues, Laura, 41, 42, 43, 44

Rundi, Christina, 45

S

Saul, Jacky, 33, 34, 35, 36, 54

Scaling-up, 69, 72

Schaap, Ab, 9, 10, 25, 26, 30, 74

Schaible, Ulrich, 51

Sheikh, Kabir 81

Short-course, 31

Sillah, Dolly Jackson, 57

Sismandis, Charalambos, 25, 26, 30, 31

Smith, Debbie, 55

Smith, Peter , 3

Smith, Steven, 53

Socioeconomic risk factors, 24

South Africa, 15, 16, 17, 19, 26, 27, 28, 29, 46, 47, 52, 62, 70, 71, 72, 73, 75

Southern Africa, 23

Stanley, Caroline, 57

Strain differentiation, 23

Surrogate marker, 32, 60

T

TARGETS, 69

TB

-infection, 38, 39

-prevalence, 24

-preventive therapy, 16, 29

-transmission, 37

-treatment, 19

TB-VAC, 53, 65

T Cells, 51, 53, 57, 59, 61, 63, 64, 65

Ten Bokum, Annemieke, 58

Time interval, 45

Treatment, 31, 32, 78

U

Uganda, 3, 56

Under-resource setting, 72

UK, 59, 63

V

Vaccines, 59, 63, 65

VCTC, 81

Verbal autopsy, 71

Viral load, 27, 46

W

Watkins, Kate, 63

Watts, Charlotte, 70

Weir, Rosemary, 59

X

Y

Young, Saroj, 64

Z

Zambia, 4, 9, 10, 11, 24, 26, 63, 64

ZAMSTAR, 26

INDEX by Funder

A

Aga Khan Foundation, 81

Anglogold, 27

Angloplatinum, 70

Aurum Institute, 15, 16, 17, 28

B

Bill and Melinda Gates Foundation, 24, 25, 26, 29, 30, 63

Brazilian Government, 41, 42, 44

British Council, 60

- C**
 Centocor, 55
 Colt Foundation, The, 47
 Commonwealth Scholarship Secretariat, 57
- D**
 DFID, 5, 6, 7, 41, 69, 71, 74, 76, 77, 78, 81
- E**
 European and Developing Countries Clinical Trials Partnership, 60
 European Commission, 53
 European Developing Countries Clinical Trials Partnership, 38
 EU, 31, 62, 65
- F**
 FIND Diagnostics, 9, 10, 11
 Ford Foundation, 70
- G**
 Gates Foundation (see Bill and Melinda Gates Foundation)
 German Science Foundation, 51
 Graf International, 7
- H**
 Heiser Foundation, The, 64
 Heptagon Fund, 8
 HIVOS Netherlands, 70
- I**
 Inter Aide, 78
 International Food Policy Research Institute (IFPRI), 73
 International Vaccine Institute, Korea, 60
- J**
- K**
 Korea Institute of Tuberculosis, 60
- L**
 LEPRA, 33, 35, 36, 54
- M**
 Ministry of Health, Malaysia, 45
 MRC, 51, 58
- N**
 Netherlands, 43
- O**
- P**
- Q**
- R**
 RENEWAL, 73
 Royal Society, 51
- S**
 SEARO, 77
 Swedish International Development Agency, 70
- T**
 Target TB, 78
- U**
 University of London, 81
 USAID, 72
- V**
- W**
 Wellcome Trust, 3, 33, 34, 35, 36, 37, 52, 54, 56, 58, 59
 WHO, 18, 20, 77
- X**
- Y**
 Yonsai College of Medicine, Korea, 60
- Z**

Produced by the TARGETS Consortium
www.lshtm.ac.uk/dfid/targets